JP6928001B2 - 心臓リモデリングの治療及び診断のためのｌｎｃＲＮＡ Ｍｅｇ３ - Google Patents

心臓リモデリングの治療及び診断のためのｌｎｃＲＮＡ Ｍｅｇ３ Download PDF

Info

Publication number
JP6928001B2
JP6928001B2 JP2018557329A JP2018557329A JP6928001B2 JP 6928001 B2 JP6928001 B2 JP 6928001B2 JP 2018557329 A JP2018557329 A JP 2018557329A JP 2018557329 A JP2018557329 A JP 2018557329A JP 6928001 B2 JP6928001 B2 JP 6928001B2
Authority
JP
Japan
Prior art keywords
meg3
seq
cardiac
nucleotides
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018557329A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019518439A5 (enExample
JP2019518439A (ja
Inventor
トゥム，トーマス
ピッコリ，マリア−テレサ
ヴェレック，ヤニカ
クマール グプタ，シャシ
クマール グプタ，シャシ
Original Assignee
メディツィニッシュ ホホシュール ハノーバー
メディツィニッシュ ホホシュール ハノーバー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メディツィニッシュ ホホシュール ハノーバー, メディツィニッシュ ホホシュール ハノーバー filed Critical メディツィニッシュ ホホシュール ハノーバー
Publication of JP2019518439A publication Critical patent/JP2019518439A/ja
Publication of JP2019518439A5 publication Critical patent/JP2019518439A5/ja
Application granted granted Critical
Publication of JP6928001B2 publication Critical patent/JP6928001B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2018557329A 2016-05-02 2017-04-26 心臓リモデリングの治療及び診断のためのｌｎｃＲＮＡ Ｍｅｇ３ Active JP6928001B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16167961.8 2016-05-02
EP16167961 2016-05-02
PCT/EP2017/059984 WO2017191021A1 (en) 2016-05-02 2017-04-26 The incrna meg3 for therapy and diagnosis of cardiac remodelling

Publications (3)

Publication Number Publication Date
JP2019518439A JP2019518439A (ja) 2019-07-04
JP2019518439A5 JP2019518439A5 (enExample) 2020-05-07
JP6928001B2 true JP6928001B2 (ja) 2021-09-01

Family

ID=56026647

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018557329A Active JP6928001B2 (ja) 2016-05-02 2017-04-26 心臓リモデリングの治療及び診断のためのｌｎｃＲＮＡ Ｍｅｇ３

Country Status (4)

Country Link
US (1) US11186838B2 (enExample)
EP (1) EP3452593B1 (enExample)
JP (1) JP6928001B2 (enExample)
WO (1) WO2017191021A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3102271A1 (en) * 2018-06-01 2019-12-05 Children's National Medical Center Compositions and methods for treating and preventing muscular disorders and dystrophies, steroid side effects, and inflammation
WO2024003205A1 (en) * 2022-06-30 2024-01-04 Medizinische Hochschule Hannover Long non-coding rnas as target for treating fibrosis and cancer
CN116179545B (zh) * 2022-09-09 2025-10-31 上海工程技术大学 LncRNA Gm20257在制备防治病理性心肌肥厚药物中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9416422B2 (en) * 2005-02-18 2016-08-16 Sloan-Kettering Institute For Cancer Research Methods for detecting minimum residual disease
WO2007097741A1 (en) * 2006-02-17 2007-08-30 The Trustees Of Columbia University In The City Of New York Method of diagnosing intrauterine growth restriction
US20120283130A1 (en) * 2010-01-15 2012-11-08 Shinya Yamanaka Method for screening induced pluripotent stem cells
US9920317B2 (en) * 2010-11-12 2018-03-20 The General Hospital Corporation Polycomb-associated non-coding RNAs

Also Published As

Publication number Publication date
US11186838B2 (en) 2021-11-30
WO2017191021A1 (en) 2017-11-09
JP2019518439A (ja) 2019-07-04
US20190136236A1 (en) 2019-05-09
EP3452593B1 (en) 2020-12-23
EP3452593A1 (en) 2019-03-13

Similar Documents

Publication Publication Date Title
JP6805304B2 (ja) 心肥大の治療および診断のためのｌｎｃＲＮＡ
EP2275545A1 (en) Use of microRNA-24 and/or its targets for the treatment and prevention of ischemia and induction of angiogenesis
US11208656B2 (en) IncRNAs GADLOR 1 and 2 for use in treating and preventing cardiac remodelling
JP6928001B2 (ja) 心臓リモデリングの治療及び診断のためのｌｎｃＲＮＡ Ｍｅｇ３
EP2255002B1 (en) Method to inhibit ribonuclease dicer, ribonuclease dicer inhibitor, and use of rna aptamers as ribonuclease dicer inhibitors
US11459561B2 (en) IncRNAS for therapy and diagnosis of angiogenesis
HK40006990B (en) Lncrnas for therapy and diagnosis of cardiac hypertrophy
HK40006990A (en) Lncrnas for therapy and diagnosis of cardiac hypertrophy
Ranjan et al. Circular RNAs in Organ Fibrosis
HK1233678B (en) Lncrnas for therapy and diagnosis of cardiac hypertrophy
HK1233678A1 (en) Lncrnas for therapy and diagnosis of cardiac hypertrophy
EP4547841A1 (en) Long non-coding rnas as target for treating fibrosis and cancer
WO2019026860A1 (ja) 遺伝子発現制御方法および遺伝子発現制御物質
TW201629216A (zh) 轉譯抑制方法及轉譯抑制劑

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20190913

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190913

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200326

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200326

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210323

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210621

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210706

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210805

R150 Certificate of patent or registration of utility model

Ref document number: 6928001

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250